Differences in Right Ventricular Function and Response to Targeted Therapy Between Patients with IPAH and PAH-CHD

Overview

Journal Front Pharmacol

Date 2023 Mar 2

PMID 36860300

Authors

Tengteng Zhu

Panyun Wu

Zhen Tan

Quan Jin

Yusi Chen

Lian Li

Zewei Chen

Yirui Tang

Jiang Li

Zhenfei Fang

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disorder characterized by elevated pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP). Right heart failure is a life-threatening complication of PAH and predicts a poor prognosis. PAH associated with congenital heart disease (PAH-CHD) and idiopathic PAH (IPAH) are two prevalent PAH subtypes in China. In this section, we set out to explore baseline right ventricular (RV) function and its response to targeted agents between IPAH and PAH-CHD. Consecutive patients diagnosed with IPAH or PAH-CHD by right heart catheterization (RHC) in the Second Xiangya Hospital from November 2011 to June 2020 were included. All patients received PAH-targeted therapy and the RV function was assessed by echocardiography at baseline and during follow-up. A total of 303 patients (age, 36.23 ± 13.10 years; women, 213 (70.3%); mean PAP [mPAP], 63.54 ± 16.12 mmHg; PVR, 14.74 ± 7.61 WU) with IPAH ( = 121) or PAH-CHD ( = 182) were included in this study. Compared with PAH-CHD, patients with IPAH had worse baseline RV function. As of the latest follow-up, forty-nine patients with IPAH and six patients with PAH-CHD died. Kaplan-Meier analyses showed better survival in PAH-CHD versus IPAH. After PAH-targeted therapy, patients with IPAH had less improvement in 6 MWD, World Health Organization functional class, and RV functional parameters compared with patients with PAH-CHD. Compared with patients with PAH-CHD, patients with IPAH had worse baseline RV function, unfavourable prognosis, and inadequate response to targeted treatment.

References

Chung L, Liu J, Parsons L, Hassoun P, McGoon M, Badesch D . Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010; 138(6):1383-94. PMC: 3621419. DOI: 10.1378/chest.10-0260. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

Ruopp N, Cockrill B . Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022; 327(14):1379-1391. DOI: 10.1001/jama.2022.4402. View

Overbeek M, Lankhaar J, Westerhof N, Voskuyl A, Boonstra A, Bronzwaer J . Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J. 2008; 31(6):1160-6. DOI: 10.1183/09031936.00135407. View

Manes A, Palazzini M, Leci E, Bacchi Reggiani M, Branzi A, Galie N . Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2013; 35(11):716-24. DOI: 10.1093/eurheartj/eht072. View

DAlonzo G, Barst R, Ayres S, Bergofsky E, Brundage B, Detre K . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5):343-9. DOI: 10.7326/0003-4819-115-5-343. View

Edward J, Banchs J, Parker H, Cornwell W . Right ventricular function across the spectrum of health and disease. Heart. 2022; 109(5):349-355. PMC: 9985748. DOI: 10.1136/heartjnl-2021-320526. View

DAlto M, Badagliacca R, Argiento P, Romeo E, Farro A, Papa S . Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. Chest. 2019; 157(2):376-383. DOI: 10.1016/j.chest.2019.09.009. View

Chandel A, Verster A, Rahim H, Khangoora V, Nathan S, Ahmad K . Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension. Pulm Circ. 2021; 11(2):20458940211012366. PMC: 8108083. DOI: 10.1177/20458940211012366. View

10.

Kawut S, Lima J, Barr R, Chahal H, Jain A, Tandri H . Sex and race differences in right ventricular structure and function: the multi-ethnic study of atherosclerosis-right ventricle study. Circulation. 2011; 123(22):2542-51. PMC: 3111939. DOI: 10.1161/CIRCULATIONAHA.110.985515. View

11.

van der Bruggen C, Tedford R, Handoko M, van der Velden J, de Man F . RV pressure overload: from hypertrophy to failure. Cardiovasc Res. 2017; 113(12):1423-1432. DOI: 10.1093/cvr/cvx145. View

12.

Rhee R, Gabler N, Sangani S, Praestgaard A, Merkel P, Kawut S . Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015; 192(9):1111-7. PMC: 4642205. DOI: 10.1164/rccm.201507-1456OC. View

13.

Sun X, Abbate A, Bogaard H . Role of cardiac inflammation in right ventricular failure. Cardiovasc Res. 2017; 113(12):1441-1452. DOI: 10.1093/cvr/cvx159. View

14.

Goh Z, Balasubramanian N, Alabed S, Dwivedi K, Shahin Y, Rothman A . Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response. Heart. 2022; 108(17):1392-1400. PMC: 9380507. DOI: 10.1136/heartjnl-2021-320733. View

15.

Shimony A, Fox B, Langleben D, Rudski L . Incidence and significance of pericardial effusion in patients with pulmonary arterial hypertension. Can J Cardiol. 2012; 29(6):678-82. DOI: 10.1016/j.cjca.2012.04.009. View

16.

Fathallah M, Krasuski R . A Multifaceted Approach to Pulmonary Hypertension in Adults With Congenital Heart Disease. Prog Cardiovasc Dis. 2018; 61(3-4):320-327. DOI: 10.1016/j.pcad.2018.07.017. View

17.

Sree Raman K, Shah R, Stokes M, Walls A, Woodman R, Perry R . Right ventricular myocardial deoxygenation in patients with pulmonary artery hypertension. J Cardiovasc Magn Reson. 2021; 23(1):22. PMC: 7938464. DOI: 10.1186/s12968-020-00694-0. View

18.

van der Bruggen C, Happe C, Dorfmuller P, Trip P, Spruijt O, Rol N . Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle. Circulation. 2016; 133(18):1747-60. DOI: 10.1161/CIRCULATIONAHA.115.020696. View

19.

Ramjug S, Hussain N, Hurdman J, Billings C, Charalampopoulos A, Elliot C . Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes. Chest. 2017; 152(1):92-102. DOI: 10.1016/j.chest.2017.02.010. View

20.

Fenstad E, Le R, Sinak L, Maradit-Kremers H, Ammash N, Ayalew A . Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis, and role of drainage. Chest. 2013; 144(5):1530-1538. DOI: 10.1378/chest.12-3033. View